Vongvaivanich K (iii) headache phase (usually unilateral, pulsating), and (iv) postdrome phase (e.g., tiredness, head pain). 3, 20, 21 The prodrome or premonitory phase may occur for hours or up to one day prior to the onset of headache in 70% of migraineurs. 22 It is composed of symptoms which may be psychological (depression, euphoria, irritability, restlessness, hyperactivity, hypoactivity, fatigue, drowsiness); neurological (photophobia, phonophobia, hyperosmia) or general (stiff neck, increased thirst, anorexia, diarrhea, constipation, fluid retention, craving for particular foods, repetitive yawning); there are also other less typical symptoms reported by some patients. [23] [24] [25] Aura symptoms occur in one fifth of migraineurs. Typical aura is characterized by fully reversible focal neurological disturbances such as visual symptoms, sensory symptoms or dysphasia / aphasia that gradually develop over ≥ 5 minutes and last for ≤ 60 minutes. 3 Visual aura is the commonest aura found in 99% of cases, followed by a sensory aura (54%), and aphasic aura (32%). 26, 27 Headaches could start simultaneously or after aura onset. However, most migraineurs (80%) usually developed the headache within 60 minutes after the end of aura. 28 In 20% of patients, headaches can consistently occur at the same side. However, in 40% of cases headaches may develop bilaterally. Head pain could be aggravated by routine physical activities such as walking or climbing stairs. Headache symptoms usually occur gradually, any sudden onset of headache should raise suspicions of secondary headache. [29] [30] [31] Postdrome phase is reported in 68% of migraineurs. Symptoms include tiredness (71.8%), head pain (33.1%), cognitive difficulties (11.7%), hangover (10.7%), gastrointestinal symptoms (8.4%), mood change (6.8%), and weakness (6.2%). Postdrome is frequently found in females (69.1%) and is associated with a full-blown migraine attack. 32 The International Classification of Headache Disorders (ICHD-2) criteria were introduced in 2004 for standard diagnosis and research. Migraine was classified into six major categories. Two major sub-types were recognized; (1) Migraine without aura is a clinical syndrome characterized by headache with specific features and associated symptoms, and (2) Migraine with aura is primarily characterized by the focal neurological symptoms that usually precede or sometimes accompany the headache. ICHD-2 criteria for diagnosis of the two major types of migraine are shown in Table 1 .
Strategies in migraine treatment
There are two approaches in migraine treatment: step care and stratified care. 33 Step care starts treating the attack with general pain-killer medications e.g., acetaminophen, NSAIDs, or combination of simple analgesics. If headaches are not responsive within two hours, migraine-specific medication such as triptan or ergot should be commenced.
In the other approach, known as stratified care, the person with migraine is firstly evaluated for severity of disability by using the Migraine Disability Assessment (MIDAS). 34, 35 This is a 5-item questionnaires which assesses lost time caused by headache over 3 months. A MIDAS score of more than '10' indicates moderate to severe disability that requires migraine-specific treatment. Another validated disability tool is the Headache Impact Test (HIT-6). A HIT-6 score more than 60 indicates severe impact from migraine. 36 The Disability in Strategies of Care (DISC) study showed stratified care is superior to step care, resulting in better patient outcomes, and also reduced time loss.
37, 38
Stratified care is recommended in current guidelines for migraine treatment.
33, 39

Nonspecific acute migraine treatment
Analgesics
NSAIDs inhibit cyclooxygenase (COX) and reduce prostaglandin within the central nervous system (CNS) and outside the blood-brain-barrier. Selective cyclooxygenase -2 (COX-2) inhibitors, refecoxib and valdecoxib, have been studied and demonstrated their efficacy in acute migraine treatment but they were withdrawn from the market because of increase in cardiovascular risk. Celecoxib, an available selective COX-2 inhibitor, could be used for acute migraine attack with doses between 100 and 400 mg. Since it causes less gastrointestinal side effects, it should be considered in people with gastrointestinal intolerance. 40, 41 Analgesics such asacetylsalicylic acid (ASA) up to 1000 mg, [42] [43] [44] naproxen 500 -1000 mg, 45 ibuprofen 200-800 mg, 46 diclofenac potassium 50 -100 mg, 47 and paracetamol 1000 mg 48 are the first medications for mild to moderate migraine. A combination of "Aspirinacetaminophen-caffeine (AAC)" elucidates higher efficacy for acute treatment in those with mild or no disability migraines, when compared to treatment with placebo or other individual analgesic. [49] [50] [51] The United States Headache Consortium recommended that NSAIDs and AAC can be effective for non-disabling migraine (Level A). 39, 52 Migraine Headaches : Acute treatment in Thailand A. At least 2 attacks fulfilling criteria B-D B. Aura consisting of at least one of the following, but no motor weakness:
1. fully reversible visual symptoms including positive features (e.g., flickering lights, spots or lines) and/or negative features (i.e., loss of vision) 2. fully reversible sensory symptoms including positive features (i.e., pins and needles) and/or negative features (i.e., numbness) 3. fully reversible dysphasic speech disturbance C. At least two of the following:
1. homonymous visual symptoms and/or unilateral sensory symptoms 2. at least one aura symptom develops gradually over ≥ 5 minutes and/or different aura symptoms occur in succession over ≥ 5 minutes 3. each symptom lasts ≥ 5 and ≤ 60 minutes D. Headache fulfilling criteria B-D for begins during the aura or follows aura within 60 minutes E. Not attributed to another disorder Vongvaivanich K -Ibuprofen 200-800 mg PO A Gastrointestinal side effects.
-Naproxen 500-1000 mg PO A Gastrointestinal side effects.
-Diclofenac-K 50-100 mg PO A Gastrointestinal side effects.
-Paracetamol 1000 mg PO A Caution in liver and kidney.
-Ergotamine tartrate and Caffeine 1 mg, 100 mg PO B Caution in cardiovascular, liver and kidney diseases.
Specific Medications
-Sumatriptan 50-100 mg PO A Caution in cardiovascular diseases. 
Classification of Recommendations.
39, 52
Level A = Established as effective, ineffective, or harmful (or established as useful/predictive or not useful/predictive) for the given condition in the specified population. (Level A rating requires at least two consistent Class I studies)
Level B = Probably effective, ineffective, or harmful (or probably useful/predictive or not useful/predictive) for the given condition in the specified population. (Level B rating requires at least one Class I study or two consistent Class II studies)
Level C = Possibly effective, ineffective, or harmful (or possibly useful/predictive or not useful/predictive) for the given condition in the specified population. (Level C rating requires at least one Class II study or two consistent Class III studies)
Level U = Data inadequate or conflicting; given current knowledge, treatment (test, predictor) is unproven.
Medications for acute migraine treatment
Ketorolac, a parenteral NSAIDs, has not yet been researched in placebo-controlled study to assess it in acute migraine treatment. The efficacy of ketorolac in acute migraine treatment was similar to meperidine and led to headache resolution similar as antiemetic medications. 53, 54 Ketorolac can be administrated intravenously at a dosage of 15 to 30 mg or intramuscularly at 30 to 60 mg per dose. The U.S. Headache Consortium recommended that intravenous or intramuscular ketorolac injection should be considered for acute treatment of migraine for whom requiring parenteral therapy (Level B). 52 Opioid use in acute migraine is generally ineffective. [55] [56] [57] The U.S. Headache Consortium stated that enteral and parenteral opioid may be added for acute migraine should the sedative effect not put patients at risk: moreover the risk for abusive use of opioids has been addressed (Level B). 52 Opioid should be limited and reserved for some particular circumstances such as pregnancy, lactation, contraindication to triptans or NSIDs (Level U). 52 Parenteral opioid should be used as a back up for acute migraine when sedation side effects will not increase patient risk and when the risk of abuse has been addressed (Level B). 52 
Antiemetics and Neuroleptics
Nausea and vomiting are common associated symptoms of migraine and can be as disabling as the headache. Antiemetic in acute migraine is recommended to treat these symptoms. It increases gastric emptying times resulting in optimizing absorption and effectiveness of oral medications. However, large prospective, placebocontrolled randomized trials are still lacking.
Intravenous metoclopramide showed superiority over placebo and ibuprofen in acute migraine treatment. 58, 59 Repeated doses of metoclopramide plus intramuscular dimenhydrinate were found to have an effectiveness similar to subcutaneous sumatriptan. 60 However, using oral metoclopramide alone, as monotherapy, is not effective for acute migraine treatment (Level A) but it can still be considered as an adjunctive therapy to NSAIDs or triptans (Level B). 52 Intravenous 10 to 20 mg metoclopramide is recommended for adults and adolescents (Level A). 39, 52 Intravenous chlorpromazine demonstrated a higher efficacy than meperidine and lidocaine.
61 Dose of 0.1 mg/kg chlorpromazine intravenously achieved a pain free response within 30 minutes compared with placebo. 62 Chlorpromazine should be used for patients requiring parenteral therapy (Level A). 52 Both metoclopramide and chlorpromazine share common side effects which include drowsiness, sedation, and hypotension. Extrapyramidal side effects such as acute dystonic reaction and akathisia are uncommon.
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Specific acute migraine treatment
Triptans
Triptans are selective 5-hydroxytryptamine (5-HT) 1B/1D-agonists and ameliorate headache without sedative effect. Agonist of serotonin-1D receptors inhibit CGRP and inflammatory neuropeptide release in the meninges that cause extravasation of dural plasma protein, and block pain transmission from peripheral trigeminal pathway to the centrally trigeminal nucleus caudalis in brain stem. They also work via the 5HT1B receptor to constrict vessels dilated by CGRP. On the present market, there are seven types of triptans: sumatriptan, zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan and frovatriptan. In Thailand, however, only two triptans are available, sumatriptan and eletriptan. Non-oral routes are also not available in Thailand. The efficacy of triptans has been proven in large placebo-controlled trials of which meta-analyses have been published. [64] [65] [66] [67] Triptans can be effective at any time during a migraine attack. However, there is evidence that the earlier triptans are taken, the better their efficacy. Triptans should be taken when the headache is mild, ideally within less than 30 minutes from onset. 74, 75 Triptans are also effective in about 60% of NSAIDs non-responder. All triptans should be used for acute treatment of mild, moderate, and severe migraine unless contraindicated (Level A). 39, 52 Sumatriptan was the first triptan to be introduced in 1991. Sumatriptan 100 mg (oral form) is significantly more effective than placebo for complete headache relief at 2 and 4 hours. Doses of 50 mg and 100 mg sumatriptan are more effective than dose of 25 mg. Dose of 50 mg is associated with a lower incident of adverse events than the dose of 100 mg. 62, 68 Sumatriptan is extensively metabolized in liver by monamine oxidase-A (MAO-A) and therefore it should not be used in patients who take MAO-A inhibitors.
Eletriptan is rapidly absorbed and has a higher bioavailability (50% vs. 14%) with longer half-life (5.5 hours vs. 2 hours) than sumatriptan. 69 Eletriptan 20, 40, and 80 mg have been studied in double blind, placebocontrolled trials which revealed that eletriptan provided higher favorable outcome compared with placebo. Eletriptan 40 mg is more effective than 20 mg and causes lower side effect than 80 mg dose. 66, [70] [71] [72] [73] Vongvaivanich K Active metabolism of eletriptan, N-desmethyl eletriptan, is catalyzed by cytochrome P-450 system (CYP3A4). Thus eletriptan should not be used with potent CYP3A4 inhibitors such as ketoconazole and clarithromycin.
Triptans are contraindicated in those with coronary artery disease, high risk for occult cardiac disease, cerebrovascular disease, peripheral vascular disease, uncontrolled hypertension, and pregnant woman. The most common adverse effects are fatigue, dizziness, asthenia and nausea. Known as triptans sensations, sensation of flushing, chest pain or chest pressure can occur in some cases and those symptoms are mild and usually transient. [64] [65] [66] Contraindication of Triptans 
Conclusion
Migraine is a common, chronic and mostly debilitating neurovascular disorder, which impairs quality of life. Its pathophysiology is still not fully discovered but cerebral hyperexcitability either from genetic mutation or environmental factors can trigger central and peripheral pain pathway. Stratified care is recommended for migraine treatment. Persons with headaches should establish the correct diagnosis and evaluate their level of disability together with impact of migraine, prior to treatment. NSAIDS and ACC are the drugs of choice for those with mild to moderate migraine headaches. Ketorolac is a solely parenteral NSAID recommended for acute migraine treatment. Opioid should be avoided due to sedative side effect and risk of abuse. Intravenous metoclopramide and chlorpromazine can be used in patients with nausea/vomiting and who require parenteral therapy. Triptans are specific treatment for acute migraine headache and should be used in disabling migraineurs in the absence of vascular contraindications. 
